https://www.thebodypro.com/category/efavirenz-sustiva-stocrin/tag/conference-coverage
Efavirenz (Sustiva, Stocrin)

Conference Coverage

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring Img

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

Promo Image

What's Hot in HIV Clinical Science

What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.

Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy Img

Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy

Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.

Promo Image

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Promo Image

What's Hot in HIV Treatment

Here’s a recap of the biggest developments in HIV treatment over the past year, as well as a look at what’s to come.

Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds Img

Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds

Mental health really matters in HIV. We got a hugely important reminder of that this month in the form of new research regarding suicide and Sustiva (one of the drugs in Atripla).

Promo Image

Is Lower-Dose Efavirenz Truly Wise for Resource-Poor Settings?

A daily dose of 400 mg of efavirenz (Sustiva, Stocrin) has been found non-inferior to the standard 600-mg dose in treatment-naive, HIV-infected individuals.

The investigators from the ENCORE1 study reported the final, 48-week results from this rando...

Promo Image

Efavirenz Interaction Studies With TB Compounds Bedaquiline and Delamanid

HIV and TB co-infection is common and treatment is complicated by drug-drug interactions.

Two poster presentations at ICAAC described potential reduced exposure of bedaquiline and a lack of interaction with delamanid when co-administered with efavi...

Promo Image

Efavirenz Levels Variable in Children in the CHAPAS-3 Study

WHO updated the guidelines for paediatric weight band dosing of efavirenz (EFV) in 2010. The generic manufacturer Cipla has developed scored 600 mg EFV tablets to facilitate appropriate weight band dosing.

These tablets are scored once on one side a...